MedPath

Oragenics Announces Termination of President's Employment Agreement and Provides Business Update

• Oragenics Inc. terminated its President's employment agreement, as disclosed in a recent SEC filing, marking a significant leadership change. • The company entered a sales agreement for an at-the-market offering of common stock, potentially raising up to $10 million. • Oragenics' ONP-002, a concussion treatment candidate, passed FDA-required safety tests and is advancing towards Phase II trials. • Recent appointments of Dr. Peacock and Dr. Kelly as Chief Clinical Officer and Chief Medical Officer, respectively, will oversee the Phase II trial.

Oragenics Inc., a biopharmaceutical company, recently announced the termination of its President's employment agreement. The decision was disclosed in a regulatory filing with the Securities and Exchange Commission (SEC). This leadership change occurs as Oragenics continues to advance its clinical programs and explore financing opportunities.

Financial and Corporate Developments

In addition to the leadership transition, Oragenics has entered into a sales agreement with Dawson James Securities Inc. for an at-the-market offering of its common stock, potentially raising up to $10 million. The company has already raised over $6 million in 2024, including approximately $4.45 million from a public offering. These funds are expected to support ongoing research and development activities.
Oragenics has also granted stock options to its President J. Michael Redmond and Chief Financial Officer Janet Huffman under its 2021 Equity Incentive Plan. Furthermore, the company has rescheduled its 2023 Annual Meeting of Shareholders from August to December 2024.

Clinical Progress of ONP-002

Oragenics is progressing with ONP-002, a product candidate for the treatment of concussions. Preclinical studies have demonstrated that ONP-002 passed FDA-required cardiotoxicity tests and showed no evidence of causing DNA damage or genotoxicity. These findings represent critical safety validations for ONP-002 as it advances towards Phase II trials. Concussions represent a significant area of unmet medical need, with limited treatment options currently available.

Leadership Team Expansion

To support the clinical development of ONP-002, Oragenics has strengthened its leadership team with the appointments of Dr. William 'Frank' Peacock as Chief Clinical Officer and Dr. James 'Jim' Kelly as Chief Medical Officer. Both will oversee the upcoming Phase II trial, bringing extensive expertise in clinical research and medical affairs.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Ocugen Q3 2024 Earnings Highlight Clinical Progress in Gene Therapy

Ocugen, Inc. reported its Q3 2024 earnings, emphasizing significant advancements in its gene therapy programs, particularly for retinitis pigmentosa and other eye diseases. Despite a slight stock price decline, the company is making strides in clinical trials, including expansion into Canada and FDA approval for an expanded access program. Financials show a cash position of $39 million and operating expenses of $14.4 million, with a recent $30 million debt financing extending the company's runway into Q1 2026.

Halozyme Abandons Evotec Acquisition, Neurogene Trial Faces Setback, Argenx Advances Myositis Program, and Kyowa Kirin Licenses Kura Oncology's Leukemia Drug

Halozyme withdrew its $2.1 billion offer to acquire Evotec after the latter declined to engage in acquisition talks, despite Halozyme's repeated attempts to initiate discussions.
A patient in Neurogene's Rett syndrome gene therapy trial died due to complications from a hyperinflammatory syndrome, a known risk associated with AAV-delivered gene therapies.

OS Therapies' OST-HER2 Shows Promise in Osteosarcoma Phase 2b Trial

OS Therapies' Phase 2b trial of OST-HER2 met its primary endpoint, demonstrating a statistically significant improvement in 12-month Event Free Survival in recurrent osteosarcoma patients.
The study indicated a higher proportion of OST-HER2 treated patients alive at 12 and 24-month timepoints compared to a historical control, suggesting improved overall survival.

Achieve Life Sciences Completes Enrollment in ORCA-OL Trial and Receives FDA Breakthrough Therapy Designation for Cytisinicline

Achieve Life Sciences completed enrollment in the Phase 3 ORCA-OL trial, evaluating the long-term safety of cytisinicline for smoking and vaping cessation, with positive initial safety review.
The FDA granted Breakthrough Therapy designation to cytisinicline for nicotine e-cigarette cessation, potentially expediting its development and review process.

Soleno Therapeutics' DCCR for Prader-Willi Syndrome Receives Priority Review from FDA

Soleno Therapeutics' New Drug Application (NDA) for DCCR (diazoxide choline) for Prader-Willi syndrome (PWS) has been accepted by the FDA and granted Priority Review.
The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of December 27, 2024, for DCCR, indicating an expedited review process.

Vertex Records First Casgevy Sale, Intra-Cellular Therapies Reports Positive Caplyta Trial Results

Vertex Pharmaceuticals reported its first commercial sale of Casgevy, a CRISPR gene therapy for sickle cell disease, generating $2 million in revenue from a patient infusion.
Intra-Cellular Therapies announced that Caplyta significantly reduced the risk of relapse in schizophrenia patients by 63% compared to placebo in a clinical trial.

FDA Lifts Clinical Hold on Ocugen's OCU200 Phase 1 Trial for Diabetic Macular Edema

The FDA has removed the clinical hold on Ocugen's investigational new drug application for OCU200, a novel treatment for diabetic macular edema (DME).
OCU200, a recombinant fusion protein, targets the integrin pathway, offering a potential solution for DME patients, including those resistant to anti-VEGF therapies.

Opdivo Approved for Perioperative Lung Cancer Treatment; Pharma Companies Announce Layoffs and Investments

Bristol Myers Squibb's Opdivo receives FDA approval for perioperative treatment of non-small cell lung cancer, reducing relapse risk by 42%.
Johnson & Johnson will invest $2 billion in a new biologics manufacturing facility in North Carolina, creating 420 jobs.

Sanofi, RadioMedix, and Orano Med Partner to Develop Radioligand Therapy for Rare Cancers

Sanofi, RadioMedix, and Orano Med have entered an exclusive licensing agreement to develop AlphaMedix for rare cancers, focusing on neuroendocrine tumors (NETs).
AlphaMedix, a targeted alpha therapy, has received FDA Breakthrough Therapy Designation for gastroenteropancreatic NETs in patients treatment-naive to peptide-receptor radionuclide therapy.

Crinetics Pharmaceuticals Announces Key Developments and Appointments

Crinetics Pharmaceuticals has announced positive Phase 2 trial results for atumelnant in treating congenital adrenal hyperplasia, participation in the 43rd Annual J.P. Morgan Healthcare Conference, and the appointment of Isabel Kalofonos as Chief Commercial Officer. Additionally, the company has granted stock options to new employees under Nasdaq Listing Rule 5635(c)(4).

Reference News

[1]
Oragenics announces termination of president's employment agreement - Investing.com
investing.com · Nov 30, 2024

Oragenics Inc. terminated its President's employment agreement, disclosed in an SEC filing. The company entered a sales ...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy